Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company's Board of DirectorsBusiness Wire • 02/03/22
Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QBusiness Wire • 11/24/21
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company's Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid TumorsBusiness Wire • 10/25/21
Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid CancersBusiness Wire • 10/11/21
Kiromic BioPharma Reports Second Quarter 2021 Financial Results and Operating HighlightsBusiness Wire • 08/13/21
Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid TumorsBusiness Wire • 07/26/21
Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid TumorsBusiness Wire • 07/16/21
KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid TumorsBusiness Wire • 06/28/21
KRBP Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell TherapyBusiness Wire • 06/17/21
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing OfficerBusiness Wire • 06/07/21
Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second QuarterBusiness Wire • 05/24/21
Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Kiromic's Proprietary Artificial Intelligence EngineBusiness Wire • 05/21/21
Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell TherapyBusiness Wire • 05/17/21
Kiromic BioPharma Reports First Quarter 2021 Financial Results and Continued Corporate ProgressBusiness Wire • 05/14/21
Kiromic Announces 6 Posters Presented at American Association of Cancer Research 2021 Showcasing our Artificial Intelligence (AI) Biomarker EngineBusiness Wire • 05/03/21
Kiromic BioPharma Reports Fiscal Year 2020 Financial Results and Continued Corporate ProgressBusiness Wire • 03/31/21
Kiromic BioPharma, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money ReportBusiness Wire • 03/26/21
Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid TumorsBusiness Wire • 03/09/21
